Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allotera Therapeutics
With
National Cancer Institute (NCI)
This is a first-in-human, multicenter, Phase 1, single-arm study in patients with R/R T-ALL/T-LBL who have exhausted other treatment options. The study evaluates dose escalation and dose expansion.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Key Eligibility Criteria:
Diagnosed relapsed or refractory T-ALL or T-LBL, as defined by World Health Organization (WHO) classification
Adequate renal, hepatic, respiratory, and cardiovascular function
Life expectancy \>12 weeks
ECOG/Karnofsky performance status 0 or 1 at screening (Adults age \>16) or Lansky Performance Status 60 and above (adolescents ≤ 16),
Clareo Health | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
